Trials / Completed
CompletedNCT02706678
Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients
Efficacy and Safety of a Post-transplantation Switch From Cyclosporin to Tacrolimus Sustained-release Capsules in Renal Transplant Recipients: A Multi-center, Open-label, Uncontrolled Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Astellas Pharma China, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the effects of tacrolimus sustained-release capsules replacing cyclosporin on kidney function of renal transplant recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tacrolimus sustained-release capsule | Oral |
Timeline
- Start date
- 2010-12-29
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2016-03-11
- Last updated
- 2024-11-08
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02706678. Inclusion in this directory is not an endorsement.